Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits

Human and Experimental Toxicology

Volumn 24, Issue 11, 2005, Pages 581-589

  Štěrba, Martin ^a   Simunek T ^b   Mazurova Y ^a   Adamcova M ^a   Popelova O ^a   Kaplanova J ^a   Ponka P ^c   Gersl V ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Iron chelator; o 108; Pyridoxal 2 chlorobenzoyl hydrazone

Indexed keywords

HYDRAZONE DERIVATIVE; PYRIDOXAL 2 CHLOROBENZOYL HYDRAZONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DEATH; DRUG SAFETY; DRUG TOLERABILITY; HISTOPATHOLOGY; IRON CHELATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; WEIGHT GAIN;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 28444496760     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327105ht571oa     Document Type: Article

References (30)

1. Aisen P, Enns C, Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol 2001; 33: 940-59.
2. Liochev SI. The mechanism of 'Fenton-like' reactions and their importance for biological systems. A biologist's view. Met Ions Biol Syst 1999; 36: 1-39.
3. Baranwal AK, Singhi SC. Acute iron poisoning: management guidelines. Indian Pediatr 2003; 40: 534-40.
4. Wong C, Richardson DR. Beta-thalassaemia: emergence of new and improved iron chelators for treatment. Int J Biochem Cell Biol 2003; 35: 1144-49.
5. Chaston TB, Richardson DR. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol 2003; 73: 200-10.
6. Voest EE, Vreugdenhil G, Marx JJ. Iron-chelating agents in non-iron overload conditions. Ann Intern Med 1994; 120: 490-99.
7. Richardson DR. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann NY Acad Sci 2004; 1012: 326-41.
8. Buss JL, Torti FM, Torti SV. The role of iron chelation in cancer therapy. Curr Med Chem 2003; 10: 1021-34.
9. Walcourt A, Loyevsky M, Lovejoy DB, Gordeuk VR, Richardson DR. Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites. Int J Biochem Cell Biol 2004; 36: 401-407.
10. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New Engl J Med 1998; 339: 417-23.
11. Brittenham GM, Nathan DG, Olivieri NF, Pippard MJ, Weatherall DJ. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003; 361: 183-84.
12. Buss JL, Hermes-Lima M, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogues. Adv Exp Med Biol 2002; 509: 205-29.
13. Baker E, Richardson D, Gross S, Ponka P. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1- naphthylaldehyde using the hepatocyte in culture. Hepatology 1992; 15: 492-501.
14. Buss JL, Arduini E, Ponka P. Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes. Biochem Pharmacol 2002; 64: 1689-701.
15. Buss JL, Arduini E, Shephard KC, Ponka P. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells. Biochem Pharmacol 2003; 65: 349-60.
16. Link G, Ponka P, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Blood 2003; 101: 4172-79.
17. Edward JT, Gauthier M, Chubb FL, Ponka P. Synthesis of new acylhydrazones as iron-chelating compounds. J Chem Eng Data 1988; 33: 538-40.
18. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998; 5: 1-28.
19. Bhattacharya M, Ponka P, Hardy P, Hanna N, Varma DR, Lachapelle P et al. Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone. Free Rad Biol Med 1997; 22: 11-16.
20. Mauricio AQ, Lopes GK, Gomes CS, Oliveira RG, Alonso A, Hermes-Lima M. Pyridoxal isonicotinoyl hydrazone inhibits iron-induced ascorbate oxidation and ascorbyl radical formation. Biochim Biophys Acta 2003; 1620: 15-24.
21. Santos NC, Castilho RF, Meinicke AR, Hermes-Lima M. The iron chelator pyridoxal isonicotinoyl hydrazone inhibits mitochondrial lipid peroxidation induced by Fe(II)-citrate. Eur J Pharmacol 2001; 428: 37-44.
22. Simunek T, Klimtova I, Kaplanova J, Sterba M, Mazurova Y, Adamcova M et al. Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacol Res 2005; 51: 223-31.
23. Horackova M, Ponka P, Byczko Z. The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H(2)O(2) injury in adult cardiomyocytes. Cardiovasc Res 2000; 47: 529-36.
24. Simunek T, Boer C, Bouwman RA, Vlasblom R, Versteilen AM, Sterba M et al. SIH - a novel lipophilic iron chelator-protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J Mol Cell Cardiol 2005; 39: 345-54.
25. Buss JL, Neuzil J, Gellert N, Weber C, Ponka P. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties. Biochem Pharmacol 2003; 65: 161-72.
26. Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 2004; 104: 1450-58.
27. Golenser J, Domb A, Teomim D, Tsafack A, Nisim O, Ponka P et al. The treatment of animal models of malaria with iron chelators by use of a novel polymeric device for slow drug release. J Pharmacol Exp Therapeut 1997; 281: 1127-35.
28. Claude JR, Claude N. Safety pharmacology: an essential interface of pharmacology and toxicology in the non-clinical assessment of new pharmaceuticals. Toxicol Letts 2004; 151: 25-28.
29. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37: 1590-98.
30. Sokol PP, Capodagli LC, Dixon M, Holohan PD, Ross CR, Coulson R et al. Cyclosporin A and vehicle toxicity in primary cultures of rabbit renal proximal tubule cells. Am J Physiol 1990; 259: C897-903.